---
title: "Lysergide (DT120) in Generalized anxiety disorder: Generic, brand name and therapeutic class of product"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Generic, brand name and therapeutic class of product. Topics: Manufacturer: Definium Therapeutics; Corporate name change from Mind Medicine (MindMed) Inc. to Definium Therapeutics, January 2026; Nasdaq ticker DFTX effective January 15, 2026; Nasdaq ticker effective date of January 13, 2026, stated January 12, 2026, superseded on January 13, 2026; 6 further topics. 10 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/generic-brand-name-and-therapeutic-class-of-product"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Generic, brand name and therapeutic class of product

<a id="heading-2.1.2.1"></a>

## 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

### Manufacturer: Definium Therapeutics

> “Definium is developing DT120 ODT, the tartrate salt form of lysergide, for generalized anxiety disorder (GAD), major depressive disorder (MDD), and posttraumatic stress disorder (PTSD), and is exploring its potential applications in other serious brain health disorders.”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

> “Our lead product candidate, DT120 (Lysergide) orally disintegrating tablet (“ODT”), is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that we are developing for the treatment of adults with generalized anxiety disorder (“GAD”), major depressive disorder (“MDD”) and posttraumatic stress disorder (“PTSD”).”

Source: [Definium Therapeutics third quarter Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/dftx-20260930.htm)

<a id="topic-2.1.2.1-2"></a>

### Corporate name change from Mind Medicine (MindMed) Inc. to Definium Therapeutics, January 2026

> “On January 9, 2026, the Company filed a Notice of Alteration with the Province of British Columbia Registrar of Companies to alter its Notice of Articles to change the Company’s corporate name from “Mind Medicine (MindMed) Inc.” to “Definium Therapeutics, Inc.” (the ”Amendment”).”
> “The Amendment was approved by the Company’s Board of Directors on January 9, 2026.”

Source: [Definium Therapeutics Form 8-K name change (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526009854/mnmd-20260109.htm)

> “On January 9, 2026, we changed our corporate name from Mind Medicine (MindMed) Inc. to Definium Therapeutics, Inc. On January 12, 2026, we changed the name of our wholly-owned subsidiary from Mind Medicine, Inc. to Definium Therapeutics US, Inc. ("Definium US"). In connection with our rebrand, we began trading on Nasdaq under the symbol “DFTX” on January 15, 2026.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.1-3"></a>

### Nasdaq ticker DFTX effective January 15, 2026

> “The Company now expects its Common Shares to begin trading on Nasdaq under the ticker symbol “DFTX” effective at market open on January 15, 2026.”

Source: [Definium Therapeutics ticker change announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/208/definium-therapeutics-common-shares-to-trade-under-new-nasdaq-ticker-symbol-dftx-effective-january-15-2026)

<a id="topic-2.1.2.1-4"></a>

### Nasdaq ticker effective date of January 13, 2026, stated January 12, 2026, superseded on January 13, 2026

> “The Common Shares will continue to trade on the Nasdaq Stock Market under the new ticker symbol “DFTX” as of market open on January 13, 2026.”

Source: [Definium Therapeutics Form 8-K name change (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526009854/mnmd-20260109.htm)

> “In conjunction with the rebrand, the Company’s Nasdaq ticker symbol will change to "DFTX" effective at market open on January 13, 2026.”

Source: [Definium Therapeutics rebrand announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/207/mindmed-rebrands-to-definium-therapeutics-advancing-a-leading-late-stage-psychiatry-pipeline-with-three-phase-3-readouts-expected-in-2026)

<a id="topic-2.1.2.1-5"></a>

### Product names: development codes DT120, MM120, and MM-120

> “This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes including DT120 (previously referred to as MM120), and DT402 (previously referred to as MM402), our lead product candidates.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

> “Under the terms of the licensing agreement, Catalent has granted MindMed access to its Zydis technology for the development of MindMed’s lead product candidate MM-120 (lysergide D-tartrate), which is a proprietary, pharmaceutically optimized form of lysergide.”

Source: [MindMed Catalent license announcement (2023)](https://ir.definiumtx.com/news-events/press-releases/detail/121/mindmed-announces-exclusive-license-agreement-with-catalent-for-its-patented-zydis-fast-dissolve-technology-for-use-with-mm-120)

<a id="topic-2.1.2.1-6"></a>

### Nonproprietary names: United States adopted name lysergide tartrate and international nonproprietary name lysergide

> “Formerly known as MM120; USAN: lysergide tartrate.”
> “Lysergide tartrate, or DT120, is our proprietary product candidate, a pharmaceutically optimized form of lysergide D-tartrate being developed for GAD, MDD and other brain health disorders.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

> “Formerly known as MM120; rINN: lysergide.”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

<a id="topic-2.1.2.1-7"></a>

### Brand name

> “In addition, any proprietary name we propose to use with our current or any other product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.1-8"></a>

### Therapeutic class: ergoline derivative and classic serotonergic psychedelic, partial agonist at 5-HT2A receptors

> “DT120 ODT is an ergoline derivative belonging to the group of classic serotonergic psychedelics, which acts as a partial agonist at 5-hydroxytryptamine serotonin-2A (5-HT2A) receptors.”
> “DT120 ODT is Definium's proprietary and pharmaceutically optimized formulation of Lysergide (LSD).”

Source: [Definium Therapeutics third quarter 2026 results announcement (2026)](https://ir.definiumtx.com/news-events/press-releases/detail/259/definium-therapeutics-reports-third-quarter-2026-financial-results-and-recent-highlights)

> “Lysergide is a synthetic ergotamine belonging to the group of classic, or serotonergic, psychedelics, which acts as a partial agonist at human serotonin-2A (5-hydroxytryptamine-2A [5-HT2A]) receptors.”

Source: [MindMed Breakthrough Therapy designation announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/137/mindmed-receives-fda-breakthrough-therapy-designation-and-announces-positive-12-week-durability-data-from-phase-2b-study-of-mm120-for-generalized-anxiety-disorder)

<a id="topic-2.1.2.1-9"></a>

### Ownership history: exclusive collaboration with the University Hospital Basel Liechti Lab from April 2020

> “On April 1, 2020, we entered into a multi-year, exclusive collaboration with Dr. Matthias Liechti’s lab at UHB (the “UHB Liechti Lab”), a leading pharmacology and clinical research group studying psychedelic substances based in Basel, Switzerland. Pursuant to the agreement, we acquired exclusive worldwide rights to data, compounds, and patent rights associated with the UHB Liechti Lab’s research with lysergide and other psychedelic compounds, including data from preclinical studies and completed or ongoing clinical trials of lysergide and MDMA.”
> “Subject to terms and conditions, the UHB Liechti Lab may receive royalties and development revenue on any commercially marketed products developed through the collaboration.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

<a id="topic-2.1.2.1-10"></a>

### Ownership history: exclusive license to Catalent Zydis orally disintegrating tablet technology, August 2023

> “In August 2023, we announced an exclusive licensing agreement with Catalent for its patented Zydis® ODT technology.”
> “The agreement also provides us with exclusive rights for the use of the Zydis technology to develop all known forms of lysergide in the United States, United Kingdom, and European Union among other key jurisdictions.”

Source: [Definium Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm)

> “MindMed holds exclusive rights to the Zydis technology for all salt and polymorphic forms of lysergide for pharmaceutical usage for the treatment of human disease and disorders in the United States, the United Kingdom, the European Union, Switzerland, Israel, and Canada.”

Source: [MindMed ODT patent announcement (2024)](https://ir.definiumtx.com/news-events/press-releases/detail/152/mindmed-announces-issuance-of-new-patent-for-mm120-orally-disintegrating-tablet-odt)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
